There have been studies using efavirenz with either AZT plus 3TC, d4T with 3TC, or d4T plus ddI, and each has shown similar rates of viral suppression at both lower and higher viral loads. The toxicities of nevirapine tend to include the risk of a rash in the first few weeks after starting the drug. In general these studies have been successful in maintaining viral suppression after the substitution. There are data that these substitutions will allow resolution in some of the side effects associated with PI's. As there are few if any lipid abnormalities seen when using triple nucleosides, one study that replaced abacavir for the PI showed normalization of the lipids in the majority of those who made the switch.
Similar data are available when nevirapine was used.
Improvements in glucose control have also been noted. Changes in body shape have been reported but may be less evident in the first six months after such substitutions, and longer term data are needed to confirm the early reports suggesting some benefit. Next Presentation Return to The Body's coverage of the 7th European Conference on Clinical Aspects and Treatment of HIV-Infection .